Parma

• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended recruitment
  2023-503501-11-00 5 2023-02-09 Metastatic Non-small Cell Lung Cancer
• OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended recruitment
  2024-511581-37-00 6 2022-11-25 Respiratory Tract Infections with Wheezing Lower Respiratory Illness
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati … Ended recruitment
  2023-503999-24-00 5 2022-06-01 Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
• A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint … Ended recruitment
  2024-516157-41-00 4 2022-05-27 Metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment
  2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
• Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended recruitment
  2024-517424-18-00 6 2022-05-10 Patients with EGFR mutant NSCLC according to TP53 mutational status
• A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lun … Ended recruitment
  2024-512127-36-00 9 2022-03-31 Non-Small Cell Lung Cancer
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• ANRS HB07 IP-Cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC d … Ended recruitment
  2024-515739-32-00 4 2022-01-10 HBV
• A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended recruitment
  2024-511837-37-00 4 2021-12-21 Relapsed/Refractory Small Cell Lung Cancer
• A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S … Ended recruitment
  2023-503674-20-00 5 2021-12-17 Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended recruitment
  2023-508738-32-00 4 2021-06-16 Previously untreated and histologically confirmed HER2-Positive (HER2
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 … Ended recruitment
  2023-505964-13-00 5 2021-03-09 Hemophilia A
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio … Ended recruitment
  2024-516481-11-00 5 2020-09-22 Metastatic Castration-Resistant Prostate Cancer
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in … Ended recruitment
  2023-505812-39-00 5 2020-08-28 HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI

Showing 121–144 of 201 trials